Positive Nachrichten in Phase II für Brustkrebs Impfstoff
Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data
WORCESTER, Mass., Dec. 6, 2010 /PRNewswire/ -- Generex Biotechnology Corporation (http://www.generex.com/) (BULLETIN BOARD: GNBT) today announced two presentations of data obtained from its on-going Phase II trial of its novel immunotherapeutic AE37 vaccine in breast cancer patients. The presentations, entitled Combination Immunotherapy: Safety and Immunologic Data from a Phase II Trial Administering a HER2/neu-derived Peptide Vaccine Sequentially or Concurrently with Trastuzumab and Increased prevalence of HLA-DR3 among breast cancer patients: implications for adjuvant HER2/neu peptide vaccine trials, will be made at the 33rd Annual San Antonio Breast Cancer Symposium (http://www.sabcs.org/) in San Antonio, Texas from December 8-12, 2010.
The presentation on combination immunotherapy reports that patients receiving both AE37 and Trastuzumab (Herceptin®), a monoclonal antibody targeting the same protein, have increased specific immune-stimulation of T cells when AE37 is given simultaneous to administration of Trastuzumab rather than following Trastuzumab treatment. These results confirm prior published reports suggesting that the combination of Trastuzumab with active immunotherapy can work synergistically in cancer patients.
The second presentation reports that patients who are genetically predisposed to less efficiently recognize peptides derived from the HER2 protein have an immunological response to the AE37 HER2 peptide vaccine that is similar in robustness to the response in patients not having this predisposition. This is promising confirmation that AE37, which is designed as a self-potentiating peptide vaccine, indeed has improved activity that may be clinically relevant.
The 2010 CTRC-AACR San Antonio Breast Cancer Symposium, an international scientific symposium for interaction and exchange among scientists and clinicians in breast cancer, is presented by Cancer Therapy&Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer. By combining their respective strengths, the San Antonio Breast Cancer Symposium encompasses the full spectrum of breast cancer research and facilitates the rapid transition of new knowledge into improved care for breast cancer patients.
http://www.finanznachrichten.de/...breast-cancer-vaccine-data-008.htm
Gruß
Dude44
|